Antitumor immunotherapy of prostate carcinoma

The progressiveness in basic immunology is leading to a better comprehension of the interaction between the immune system and tumours. It arouses the interest in the use of the immune system in cancer treatment. Preclinical and clinical studies of the antitumour immunotherapy report promising results of several tested substances. These results also illustrate the basic operating principles of the immune system. The best illustration of the hopes put into antitumour immunotherapy is a recent approval of a substance for prostate cancer treatment called Sipuleucel-T by the American Food and Drug Administration (FDA). This work summarizes recent findings in the development of strategies for the antitumour immunotherapy of prostate cancer, but most of these findings and strategies are applicable for other types of cancer as well